Popular Articles

Turning over a new leaf
Private equity: The private equity industry was challenged in 2009. Deal flow remained slow, portfolio companies struggled and investors in buyout funds scrambled to meet their cash commitments. Rebounding bond and equity markets helped some firms in the second half. But the rally was too late for others. As the industry enters a new decade, expect the divide between the sheep and goats of the buyout world to widen.

Nasdaq Composite slips 2%; ICICI Bank ADR soars
The US markets ended on a negative note on Friday.

News of the day

Snyder to take over as Dean of Yale School of Management
University of Chicago"s Booth School of Business (SOM) Dean, Edward Snyder will take over as the Dean of Yale School of Management in July 2011.
Online Business

Pharma ind seeks govt assistance on takeover concerns

Concerned over the recent takeover of some firms by Multi National Companies (MNCs), the domestic pharmaceutical industry has asked the government to protect and promote it by making available funds for research and development. - CBI seeks govt nod for full probe on Sibal - NCP, Cong meet to resolve portfolio sharing - Govt mulls PSU disinvestment piggyriding on FPOs - Stimulus to stay; may cut oil, fert subsidies: FM - NCP ready to support Maha govt from outside: Bhujbal - Govt to contest EU"s probe on steel fasteners In a letter to the department of pharmaceuticals, Indian Pharmaceutical Alliance (IPA) has said lack of available funding is the main reason for the recent spurt in the sale of stakes in domestic companies. "In view of your concern and interest in promoting growth and development of pharmaceutical industry, we urge you to examine this phenomenon and consider appropriate funding mechanism to protect and promote the domestic industry," IPA said. Since June last year, multinationals have acquired six drug comopanies, including the Rs 22,000 crore takeover of Ranbaxy Laboratories by Japanese drug maker Daiichi Sankyo. According to industry experts, drying up of product pipelines of MNCs are forcing them to buy up Indian firms to a get a hold on the generic business globally. Of late, there have been reports of majors like Pfizer scouting the Indian market for acquisitions. The association said the sell-outs have highlighted the need for an "appropriate funding mechanism" to meet the challenges faced by Indian pharma companies. Also, these have exposed the limitations of the current policy framework of providing weighted deduction for R&D and meagre amounts granted under Market Development Assistance (MDA) programme, it said.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):